Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Drug Resistance
100%
Oncogenic Pathways
100%
Leukemia
100%
Casein Kinase 2
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
High Risk
100%
CX-4945
41%
Bcl-xL
41%
Folic Acid
33%
Therapeutic Efficacy
25%
Specific Inhibitor
16%
Methotrexate
16%
Combination Treatment
16%
Dehydrogenase
16%
5-methyltetrahydrofolate
16%
Methotrexate Treatment
16%
Doxorubicin
16%
High-level Expression
16%
NADP+
16%
Thymidylate Synthase
16%
Pathway Genes
16%
Transcriptional Regulator
16%
Tumor Suppressor Activity
8%
Poor Prognosis
8%
Molecular Mechanism
8%
Chemotherapy
8%
Published Data
8%
Pediatric
8%
Combination Therapy
8%
DNA-binding Proteins
8%
Oncogenic Kinases
8%
Tumor Suppressor
8%
Tumor Suppression
8%
Treatment Strategy
8%
Pathway Inhibitors
8%
Pediatric Patients
8%
In Vivo Efficacy
8%
Leukemia Therapy
8%
Overexpression
8%
In Vivo Applications
8%
Enhanced Resistance
8%
Transcriptional Repressor
8%
Novel Combinations
8%
Acute Lymphoblastic Leukemia Cells
8%
Apoptotic Genes
8%
Patient-derived Xenograft
8%
DNA Binding Affinity
8%
Specific Aims
8%
Metabolic Pathways
8%
Mechanistic Insights
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Leukemia
100%
Casein Kinase
100%
Drug Resistance
100%
Casein Kinase II
100%
Carcinogenesis
100%
Folic Acid
41%
Methotrexate
33%
Doxorubicin
33%
Tumor Suppressor Protein
25%
Thymidylate Synthase
16%
Methylenetetrahydrofolate Dehydrogenase
16%
Combination Therapy
8%
Cytotoxicity
8%
Diseases
8%
Phosphotransferase
8%
DNA Binding Protein
8%
Antiapoptotic
8%
Cancer Inhibition
8%
Chemotherapy Regimens
8%